Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL

Cutaneous T-cell lymphomas (CTCL) are a rare group of heterogeneous disorders characterized by cutaneous involvement of monoclonal T-lymphocytes. Although indolent at early stages, CTCL can confer significant morbidity, and mortality when advanced. There is an unmet need for tolerable and durable tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Shaheer, Sawas, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683760/
https://www.ncbi.nlm.nih.gov/pubmed/31417860
http://dx.doi.org/10.3389/fonc.2019.00645
_version_ 1783442150118129664
author Khan, Shaheer
Sawas, Ahmed
author_facet Khan, Shaheer
Sawas, Ahmed
author_sort Khan, Shaheer
collection PubMed
description Cutaneous T-cell lymphomas (CTCL) are a rare group of heterogeneous disorders characterized by cutaneous involvement of monoclonal T-lymphocytes. Although indolent at early stages, CTCL can confer significant morbidity, and mortality when advanced. There is an unmet need for tolerable and durable treatments with antibodies recently gaining promise. Here we review approved systemic therapies and discuss select antibodies in development.
format Online
Article
Text
id pubmed-6683760
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66837602019-08-15 Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL Khan, Shaheer Sawas, Ahmed Front Oncol Oncology Cutaneous T-cell lymphomas (CTCL) are a rare group of heterogeneous disorders characterized by cutaneous involvement of monoclonal T-lymphocytes. Although indolent at early stages, CTCL can confer significant morbidity, and mortality when advanced. There is an unmet need for tolerable and durable treatments with antibodies recently gaining promise. Here we review approved systemic therapies and discuss select antibodies in development. Frontiers Media S.A. 2019-07-30 /pmc/articles/PMC6683760/ /pubmed/31417860 http://dx.doi.org/10.3389/fonc.2019.00645 Text en Copyright © 2019 Khan and Sawas. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Khan, Shaheer
Sawas, Ahmed
Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL
title Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL
title_full Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL
title_fullStr Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL
title_full_unstemmed Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL
title_short Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL
title_sort antibody-directed therapies: toward a durable and tolerable treatment platform for ctcl
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683760/
https://www.ncbi.nlm.nih.gov/pubmed/31417860
http://dx.doi.org/10.3389/fonc.2019.00645
work_keys_str_mv AT khanshaheer antibodydirectedtherapiestowardadurableandtolerabletreatmentplatformforctcl
AT sawasahmed antibodydirectedtherapiestowardadurableandtolerabletreatmentplatformforctcl

Ejemplares similares